Karen Aymonnier

Karen Aymonnier

Auto-generated profile, based on publicly available information

Karen Aymonnier

Université Paris Cité, INSERM U1016

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
KAKaren Aymonnier
Karen Aymonnier
JNJulie Ng
Julie Ng
LFLaura E. Fredenburgh
Laura E. Fredenburgh
KZKatherin Zambrano-Vera
Katherin Zambrano-Vera
PMPatrick Münzer
Patrick Münzer
DWDenisa Wagner
Denisa Wagner
Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) engages the inflammasome in monocytes and macrophages and leads to the cytokine storm in COVID-19. Neutrophils, the most abundant leukocytes, release neutrophil extracellular traps (NETs), which have been implicated in the pathogenesis of COVID-19. Our recent study shows that activation of the NLRP3 inflammasome is important for NET release in sterile inflammation. However, the role of neutrophil inflammasome formation in human disease is unknown. We hypothesized that SARS-CoV-2 infection may induce inflammasome activation in neutrophils. We also aimed to assess the localization of inflammasome formation (ie, apoptosis-associated speck-like protein containing a CARD [ASC] speck assembly) and timing relative to NETosis in stimulated neutrophils by real-time video microscopy. Neutrophils isolated from severe COVID-19 patients demonstrated that ∼2% of neutrophils in both the peripheral blood and tracheal aspirates presented ASC speck. ASC speck was observed in neutrophils with an intact poly-lobulated nucleus, suggesting early formation during neutrophil activation. Additionally, 40% of nuclei were positive for citrullinated histone H3, and there was a significant correlation between speck formation and nuclear histone citrullination. Time-lapse microscopy in lipopolysaccharide -stimulated neutrophils from fluorescent ASC reporter mice showed that ASC speck formed transiently and at the microtubule organizing center long before NET release. Our study shows that ASC speck is present in neutrophils from COVID-19 patients with respiratory failure and that it forms early in NETosis. Our findings suggest that inhibition of neutrophil inflammasomes may be beneficial in COVID-19.

21 November 2022 in Immunological Reviews
Verified
Journal Article
Open access
KAKaren Aymonnier
Karen Aymonnier
JAJennifer Amsler
Jennifer Amsler
PLPeter Lamprecht
Peter Lamprecht
ASAlan Salama
Alan Salama
VWVéronique Witko‐Sarsat
Véronique Witko‐Sarsat
Summary: The term “vasculitis” refers to a group of rare immune‐mediated diseases characterized by the dysregulated immune system attacking blood vessels located in any organ of the body, including the skin, lungs, and kidneys. Vasculitides are classified according to the size of the vessel that is affected. Although this observation is not specific to small‐, medium‐, or large‐vessel vasculitides, patients show a high circulating neutrophil‐to‐lymphocyte ratio, suggesting the direct or indirect involvement of neutrophils in these diseases. As first responders to infection or inflammation, neutrophils release cytotoxic mediators, including reactive oxygen species, proteases, and neutrophil extracellular traps. If not controlled, this dangerous arsenal can injure the vascular system, which acts as the main transport route for neutrophils, thereby amplifying the initial inflammatory stimulus and the recruitment of immune cells. This review highlights the ability of neutrophils to “set the tone” for immune cells and other cells in the vessel wall. Considering both their long‐established and newly described roles, we extend their functions far beyond their direct host‐damaging potential. We also review the roles of neutrophils in various types of primary vasculitis, including immune complex vasculitis, anti‐neutrophil cytoplasmic antibody‐associated vasculitis, polyarteritis nodosa, Kawasaki disease, giant cell arteritis, Takayasu arteritis, and Behçet's disease.

5 August 2019 in Blood
Verified
Journal Article
Closed access
KAKaren Aymonnier
Karen Aymonnier
CKCharlotte Kawecki
Charlotte Kawecki
LVLaurence Venisse
Laurence Venisse
YBYacine Boulaftali
Yacine Boulaftali
OCOlivier Christophe
Olivier Christophe
MBMarie-Christine Bouton
Marie-Christine Bouton
Targeting natural anticoagulant proteins as a means to rebalance the hemostatic system is an emerging trend in the development of innovative therapeutic strategies for hemophilia. These 2 articles develop these concepts in the areas of hemostasis and contact activation. In the study by Aymonnier and colleagues, simple amino acid substitutions converted a serpin elastase inhibitor, α1-antitrypsin (α1AT), into a potent antithrombin, activated protein C inhibitor, or anti-PKa/FXIIa inhibitor. In the study by de Maat and colleagues, redesign of α1AT strongly altered its inhibitory behavior and enables it to be used for the treatment of contact system–mediated thrombosis and inflammation.

4 June 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
CKCharlotte Kawecki
Charlotte Kawecki
KAKaren Aymonnier
Karen Aymonnier
SFStephen Ferrière
Stephen Ferrière
LVLaurence Venisse
Laurence Venisse
VAVéronique Arocas
Véronique Arocas
CDCécile V. Denis
Cécile V. Denis

3 April 2026
Verified
Thesis
Closed access
KAKaren Aymonnier
Karen Aymonnier
L’hémophilie A est une maladie hémorragique rare caractérisée par un déficit du facteur de la coagulation VIII (FVIII). De nouvelles stratégies thérapeutiques ne reposant pas sur l’injection de FVIII se développent. Nous proposons une approche innovante qui consiste à cibler un anticoagulant naturel présent dans les plaquettes, la Protéase Nexine-1 (PN-1). La PN-1 est un inhibiteur puissant de la thrombine, enzyme clé de la coagulation. Bloquer la PN-1 favoriserait ainsi la génération de thrombine et donc la coagulation chez les patients hémophiles. Nous avons montré que bloquer la PN-1 améliore effectivement la génération de thrombine dans les plasmas de patients hémophiles. Nos données obtenues in vivo ont également montré une restauration de la coagulation et des temps de saignement chez des souris hémophiles déficientes en PN-1. L’ensemble de nos résultats indique que la PN-1 constitue une nouvelle cible thérapeutique intéressante pour le traitement de l’hémophilie.Le rôle potentiel de la PN-1 dans la régulation des mécanismes inflammatoires n’est pas connu. Au niveau des cellules inflammatoires, sa présence n’a été démontrée que dans les monocytes-macrophages et son expression n’a encore jamais été étudiée dans les polynucléaires neutrophiles. Nous avons ainsi mis en évidence pour la première fois la présence de PN-1 dans les neutrophiles et avons montré que le déficit en PN-1 limite le recrutement des neutrophiles in vivo. Ces travaux ont permis d’identifier la PN-1 comme un nouveau régulateur des mécanismes de recrutement des neutrophiles.

12 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
CLChloé Lopes
Chloé Lopes
KAKaren Aymonnier
Karen Aymonnier
NCNicolas Cagnard
Nicolas Cagnard
GFGéraldine FALGARONE
Géraldine FALGARONE
LTLéa Tourneur
Léa Tourneur
Key components of innate immune responses, the NLRP3 sensor, ASC adaptor and Caspase-1 effector form the NLRP3 inflammasome, whose assembly leads to both inflammatory cytokines secretion and cell death. Its priming and activation are regulated by numerous proteins including the serine/threonine kinase NEK7. PCNA is a nuclear scaffolding protein essential for DNA replication. In neutrophils, which are differentiated cells deprived of proliferative capacity, PCNA is exclusively cytoplasmic and regulates neutrophil functions through interactions with different protein partners. Among them, pro-Caspases-3/8/9/10 interact with PCNA to regulate apoptosis. We therefore hypothesize that cytoplasmic PCNA could serve as a regulatory platform for the NLRP3 inflammasome via its interaction with its components. In PMA-differentiated THP-1 macrophages, PCNA relocalized mainly in the cytoplasm. Furthermore, PCNA scaffold inhibitors inhibited IL-1β secretion, pro-Caspase-1 cleavage and pyroptosis-activating gasdermin D cleavage, induced by either nigericin, monosodium urate crystals or Escherichia coli bacteria. Nigericin-stimulation resulted in cytoplasmic PCNA binding to NEK7 and potentially NLRP3, and the p21 peptide, the highest competitive inhibitor of PCNA partner binding, disrupted PCNA-NEK7 interaction. Finally, use of bone marrow-derived macrophages from p21 knockout mice suggested that the cyclin-dependent kinase inhibitor p21 might be a natural repressor of the NLRP3 inflammasome. This work provides a proof-of-principle for the potential of disrupting PCNA interactions to regulate both canonical and non-canonical NLRP3 inflammasomes.